Blog

  • China’s Meteoric Rise Into Space

    China’s Meteoric Rise Into Space

    While NASA maintains the lead in human space exploration, other nations have already begun their own projects. Take the China National Space Agency for example, with their CLEP, or Chinese Lunar Exploration Program. If you have any doubts about the objectives of the program, just check out their logo: a stylized crescent moon with two footprints in the middle.

    The logo is meant to also resemble the Chinese character for “Moon”, which in my opinion is rather clever.

    Now as we’ve seen with NASA and Artemis, plans are easy to announce but slightly harder to execute. That said, the Chinese have managed quite a few accomplishments in a short period of time.

    On October 24, 2007 the Chinese launched the Chang’e 1 mission, named for the traditional goddess of the moon. This was the first launch of Phase I of the plan, which focused solely on orbital missions. The orbiter was a success, providing a detailed map of the entire lunar surface and doing some long-range scouting for future landing sites.

    That missions was followed three years later with the appropriately named Chang’e 2, which did the same thing but in greater detail, then sped off to visit the asteroid 4179 Toutatis to help the agency test its communications and command systems.

    In 2013 the Chinese upped the ante with Chang’e 3 (can you sense a pattern here?), which was the first soft landing on the moon achieved by that agency. That mission too was a great success, especially with the deployment of a small rover, Yutu.

    In fact, that mission was so successful that it delayed the launch of Chang’e 4 because they wanted to add more capabilities to it. On January 3, 2019 the lander reached the South Pole-Aitken Basin on the far side of the moon, which also carried a rover with it, Yutu-2, the first ever rover to explore the far side.

    Next up was Phase III, a pair of robotic sample-return missions. The first of missions was just a test, and the second one, Chang’e 5, launched in November 2020 and returned to Earth with 1,731 grams of lunar soil – the first samples to return to Earth since the Apollo era.

    The latest mission is, you guessed it, Chang’e 6, which launched on May 3, 2024. This mission was the whole package: a lander back at the South Pole-Aitken Basin, a successful sample return of more lunar material, and a new rover, the Jinchan, to explore the far side some more, because we just can’t get enough of that farside.

    While these are all great successes, they were all uncrewed robotic missions. The next in the series, Chang’e 7 expected to launch in 2026 and Chang’e 8 two years later, will begin to set the stage for human presence, developing a sort of robotic base of landers and rovers, with orbiters monitoring the whole thing and relaying communications back and forth to Earth, to test one of the most important aspects of a future lunar base: ISRU.

    ISRU is an acronym that you’ll hear a lot about when it comes to future plans for the Moon, Mars, and beyond, and it stands for in-situ resource utilization. The basic idea is that launching stuff to the Moon is expensive…really expensive. And if we want any sort of base or installation there, it would require an enormous amount of resources like air, water, food, and structures to make it happen. So a cleverer approach is to use lunar soil, or regolith, to fabricate structures and pull out useful resources like water. It’s not like we could just 3D print a lunar base out of regolith, but the more we’re able to use local resources, the better our prospects for future long-term habitation.

    After this, things start to get a little fuzzy with the Chinese plans. They have announced that they want to send a human mission to the Moon in 2029 or 2030. The mission will require a much beefier launch vehicle than their current capabilities, named the Long March 10, which is currently in development. Think of it like the Chinese version of the SLS or Atlas V, a single-use vehicle designed to throw as much at the Moon as possible. The current plants for it to be capable of lofting 70 tons into low-Earth orbit and 27 tons towards the Moon.

    Even with this kind of lift capacity, however, the hypothetical crewed mission will still require two launches: one for the lander, and another for the spacecraft to
    take the crew to the Moon. That crew would land on the surface, spend a few days poking around and looking at rocks (I’m just kidding, they’d be doing some intense flight testing and science), and return. A retread of the Apollo-style missions, for sure, but a retread is better than what we have right now, which is…nothing. So good for them.

    All the components of that mission: the spacecraft, the lander, the spacesuits, all of it, are still under active development. Chinese space officials and leaders tend to keep their cards close to their chest, and it’s not like NASA where the budget undergoes regular public reviews. On the other hand, it’s pretty difficult (as in, impossible) to keep launches and space activity secret, so we know when the Chinese are able to accomplish something, but we don’t know if programs are over budget or facing major delays or technical hurdles.

    It’s anybody’s guess if that expected launch date of 2029 or 2030 is reliable or not. When it comes to the Chinese, we’ll just have to wait and see.

    Continue Reading

  • Artificial Intelligence Is Changing the Way We Navigate Romantic Relationships

    Artificial Intelligence Is Changing the Way We Navigate Romantic Relationships

    After a painful breakup, 28-year-old Mikaela Wild, a social media content strategist in Los Angeles, sat on her couch, phone in hand. Wary of bombarding a friend and without a therapist to consult, she opened ChatGPT and plugged in a summary of her three-year relationship, concluding with the question, “Why didn’t things work out?”

    What followed were several exchanges in which she processed her relationship not with a human, but with artificial intelligence.

    Wild isn’t alone. Whether they’re crafting emotionally intelligent texts, roleplaying tough conversations, or providing advice in moments of uncertainty, chatbots like ChatGPT, Replika, and Gemini are playing an increasingly prominent role in the way people navigate their romantic lives. And so, a question emerges: What happens to love, intimacy, and emotional growth when our most vulnerable moments are processed with machines?

    Orange County-based dating and relationship coach Kimberly Rae says she’s seeing a noticeable shift in how clients seek guidance. “I have conversations with clients every day about AI, and how they’re using it for their dating profiles or to draft a ‘Hey, this isn’t working’ text.”

    While Rae believes that AI can be a useful tool, she warns that it can also stymie true intimacy. “At a certain point it can become a crutch, because it takes away your real voice and your authenticity,” she says. “Relationships are built on raw, in-the-moment exchanges, not perfectly curated dialogue. And the more we polish our words, we’re just gonna risk more emotional distance.”

    A 2024 survey by Wingmate—the AI-powered dating assistant—found that 41% of young adults have used AI to initiate a breakup, with women being slightly more likely than men to utilize the tool. Additionally, 57% of young adults said they’d trust AI over a friend for relationship and dating advice. Whether it’s for scripting texts, decoding mixed signals, or simulating closure, AI is fast becoming the preferred confidant of a whole generation of daters.

    When 33-year-old Nicole Matteson, an inside sales representative in Bend, Oregon, went through a breakup in June, she deliberately avoided going to close friends for advice, thinking their feedback would be biased. Instead, she went to ChatGPT, which she says helped her to reframe the situation and recognize behavioral patterns, attachment styles, and dynamics she had not previously considered. ”If my ex and I were having a random argument or if I felt I misunderstood something, I would take that information, put it into ChatGPT, and be like, ‘Help me break this down.’” In response, she says that ChatGPT gave her a logical, nuanced perspective on a situation that had confused her. “I feel like it’s helped me understand myself a lot more, which in turn has helped me to communicate more effectively,” says Matteson.


    Continue Reading

  • BISE Sargodha matric toppers 2025: Check list of position holders – ARY News

    1. BISE Sargodha matric toppers 2025: Check list of position holders  ARY News
    2. Student from Lawrence College tops Pindi board’s SSC exams  Dawn
    3. BISE reveals matric position holders  The Express Tribune
    4. Secondary School Annual Exams: Lahore Board announces results  Business Recorder
    5. BISE Multan Class 10th Result 2025 Officially Announced  TechJuice

    Continue Reading

  • Basic cybersecurity lapses are leaving US infrastructure exposed, top experts warn – Nextgov/FCW

    1. Basic cybersecurity lapses are leaving US infrastructure exposed, top experts warn  Nextgov/FCW
    2. Emerging Trends in State Cyber Policy During the 2025 Legislative Session  Tech Policy Press
    3. Dwindling federal cyber support for critical infrastructure raises alarms  Cybersecurity Dive
    4. John Wargo: A federal policy that endangers our state’s cybersecurity  Pittsburgh Post-Gazette

    Continue Reading

  • Starlink outage: Tens of thousands report issues

    Starlink outage: Tens of thousands report issues

    FILE – Starlink is displayed on a mobile phone in this photo illustration in Brussels, Belgium, on July 18, 2025. (Photo illustration by Jonathan Raa/NurPhoto via Getty Images)

    Tens of thousands of people across the world reported issues with Starlink on Thursday, according to Downdetector. 

    What they’re saying:

    Starlink confirmed it was experiencing a network outage and said it was “currently in a network outage” and was working to fix the issue. 

    The backstory:

    Starlink operates the world’s largest satellite constellation with over 6,750 satellites currently orbiting Earth to provide low-latency broadband, including to areas where internet previously has been completely unavailable.

    The Source: Information for this article was taken from the Downdetector website, a tweet from Starlink on July 24, 2025, and previous reporting by The Associated Press. 

    WorldElon MuskTechnology

    Continue Reading

  • Italy’s Boninfante celebrates a season of medals and milestones

    Italy’s Boninfante celebrates a season of medals and milestones

    Every athlete experiences a moment – or period – that defines their career, and for Mattia Boninfante, the 2024-25 season was exactly that. The Italian volleyball player had an outstanding year, shining both with his club and the national team. His journey reached a new high on Thursday, 24 July as Italy defeated Japan 3-1 in the men’s bronze-medal match at the Rhine-Ruhr 2025 FISU World University Games.

    After a bitter semifinal loss to Brazil in five sets on Wednesday, the Italians bounced back to claim third place at the end of another intense battle.

    “We feel good. It’s not easy to step onto the court at the beginning, especially for a third-place final, because there’s often still some bitterness from the semifinal,” said the physical education and sport student from  Pegaso Telematic University in Napoli.

    “But we did well to move forward, to channel the disappointment and frustration we felt after the loss, and that allowed us to play this match. We’re really happy because winning a medal is always a great feeling,” the setter added right after the match.

    This wasn’t Boninfante’s first success at an international level. In recent years, he had already earned multiple medals in European and World Cups as part of Italy’s junior squads. However, the 2024-25 campaign marked a turning point in his career: his first-ever call-up to the senior national team. The 21-year-old made his debut during the first week of the Volleyball Nations League (VNL) in Canada in June.

    “I have to say it’s an amazing feeling. These were my very first matches with the senior national team, so I’m definitely very happy. It’s the dream you always have when you start playing volleyball.”

    Reflecting on the differences between the FISU Games and senior competitions, Boninfante added, “Maybe, on average, since there’s no age limit in the senior national team, the level is more balanced. Here, with some teams, you can feel there’s a gap at first, but especially as you move on to the semifinals and final, the games get much tougher, and winning requires real effort.

    “But matches like these help us get used to playing at this level, in tight matches, where a single point can decide the outcome of the game, as we saw in the first sets today and in the semifinal. That’s why you need to stay fully focused from start to finish.”

    Awards, achievements and ambitions

    But this year wasn’t just about international success for the student-athlete. Just a few days before the FISU Games kicked off, Boninfante was named Best Italian U23 Player, a prestigious individual recognition that added to an already exceptional season with his club, Cucine Lube Civitanova, which won the Italian Cup and finished as runners-up in the Serie A Championship.

    The Italian men’s volleyball team after winning the bronze medal at the Rhine-Ruhr 2025 FISU Games © Frederic Scheidemann / Rhine-Ruhr 2025

    “I feel absolutely great and I take a lot with me from these experiences. First of all, I now have a better sense of what it means to play so many matches in a single year (…), so if my goal is to play volleyball for many years, I need to get used to this kind of workload. Also, gaining experience by playing high-level matches really helps me be even more prepared in the future,” he said.

    And when it comes to the future, Boninfante is clear about his mindset and goals.

    “The goal is to keep improving, there’s always something to learn. It’s about identifying what you’re not doing well and working on it to keep getting better.”

    Poland dominated Brazil in straight sets later on Thursday to capture the FISU Games men’s volleyball gold medal.

    The Rhine-Ruhr 2025 FISU World University Games take place from 16-27 July. Watch all the competitions live on fisu.tv. Click on the link to find the full schedule.

    Written by Valentina Rasini, EU U-Media Ambassador, Italy

    The Young Reporters Programme exemplifies FISU’s commitment to more than sports competitions. At every FISU World University Games, a group of talented aspiring sports journalists are chosen to cover the competition.

    We warmly thank FISU Official Partner Qiaodan Ltd. which provides remarkable uniforms to FISU Family and International Technical Officials since 2015. Qiaodan is a valuable partner for FISU as it continued to provide its support during the postponement of events due to the global pandemic, and recently extended the relationship with FISU up to and including 2025.

    Continue Reading

  • Remote CBT for Chronic Pain Shows Modest but Lasting Benefits

    Remote CBT for Chronic Pain Shows Modest but Lasting Benefits

    Credit: Adobe Stock/ AntonioDiaz

    New research showed remote, scalable cognitive behavioral therapy (CBT) for chronic pain brought moderate improvements in pain and related functional or quality-of-life outcomes.

    “Findings suggest that centralizing delivery of the CBT-CP-based programs via telephone/videoconferencing and online interventions is effective, with potential for widespread dissemination into clinical care and health care organizations nationwide,” wrote investigators, led by Lynn L. DeBar, PhD, MPH, from Kaiser Permanente Center for Health Research, in Portland, Oregon.

    Patients can turn to many nonpharmacologic options to manage chronic pain—exercise, nutrition, mind-body techniques, acupuncture, or spinal manipulation. CBT interventions are the first-line nonpharmacologic option for chronic pain, but they are not easily accessible; urban areas may have limited CBT-trained clinicians. With virtual CBT options, this could be a way for patients with chronic pain to get relief.

    Investigators sought to examine the effectiveness of remote, scalable CBT-based chronic patient treatments compared with usual care in the phase 3 randomized RESOLVE trial. The study included 2331 patients aged ≥ 18 years with high-impact chronic musculoskeletal pain from 4 US health care systems: Kaiser Permanente Georgia (northern Georgia), Kaiser Permanente Northwest (Oregon and southwest Washington), Kaiser Permanente Washington (Washington and Idaho), and Essentia Health (northern Minnesota, eastern North Dakota, and northern Wisconsin). Participants were included if they had at least 1 or 2 outpatient visits more than 60 days apart for nonmalignant musculoskeletal pain within the past 360 days, if they had high-impact chronic pain determined by the Graded Chronic Pain Scale-Revised, and a 12 or higher on the Pain, Enjoyment of Life, and General Activity scale.

    Participants were randomized 1:1:1 to receive either:

    · 8 CBT sessions led by a health coach via telephone or videoconferencing (n = 778)

    · 8 CBT sessions via online self-completed program (painTRAINER) (n= 776)

    · Usual care plus a resource guide (n = 777).

    The study took place between January 2021 and February 2023. Follow-up finished in April 2024. The primary outcome was meeting or exceeding the minimal clinically important difference (MCID) in pain severity score (≥ 30% decrease; score range, 0 – 10) on the 11-item Brief Pain Inventory-Short Form from baseline to 3 months. Secondary time points were 6 and 12 months from baseline.

    Other secondary outcomes, measured at 3, 6, and 12 months, included pain intensity, pain-related interference, Patient-Reported Outcomes Measurement Information System (PROMIS), social role and physical functioning, and patient global impression of change.

    The sample had a mean age of 58.8 years, 74% women, and 44% rural or medically underserved. The majority completed the trial (94.8%).

    At 3 months, the adjusted percentage of participants achieving ≥ 30% in the pain severity score was 32.0 (95% confidence interval [CI], 29.3 – 35.0) in the health coach group, 26.6 (95% CI, 23.4 – 30.1) in the painTRAINER group, and 20.8 (95% CI, 18.0 – 24.0) in the usual care group. The health coach and painTRAINER groups were significantly more likely to achieve an MCID in pain severity compared to controls (relative risk [RR], 1.54; 95% CI, 1.30 – 1.82 and RR, 1.28; 95% CI, 1.06 – 1.55, respectively).

    Ultimately, the health coach program was more effective than the painTRAINER (RR, 95% CI, 1.03 – 1.40) at 3 months. However, compared with usual care, both interventions brought statistically significant benefits

    “The modest benefit of active CBT-based interventions over usual care was sustained during longer-term follow-up (6 and 12 months), with no relative benefit observed for the health coach group compared with the painTRAINER group at these later points,” investigators wrote.

    References

    1. DeBar LL, Mayhew M, Wellman RD, et al. Telehealth and Online Cognitive Behavioral Therapy-Based Treatments for High-Impact Chronic Pain: A Randomized Clinical Trial. JAMA. Published online July 23, 2025. doi:10.1001/jama.2025.11178
    2. Non-Drug Approaches to Chronic Pain. https://www.va.gov/WHOLEHEALTHLIBRARY/tools/non-drug-approaches-to-chronic-pain.asp. Accessed July 24, 2025.

    Continue Reading

  • Marcus Rashford makes instant impression on Barcelona squad as journalist reveals dressing room feelings

    Marcus Rashford has made an instant impression on the Barcelona squad following his first training session.

    Rashford has joined Barca from Manchester United on a season-long loan.

    The Catalan giants will cover the entirety of the star forward’s wages after he agreed to take a pay cut and they have the option to make the transfer a permanent deal for £30 million in 2026.

    Rashford has gone through his paces in training following his switch but he will have to wait to make his debut after the club cancelled their scheduled pre-season game against Vissel Kobe on Sunday due to a ‘serious breach of contract’.

    He will be looking to make his Barca bow next Thursday when they face FC Seoul.

    Ahead of potentially making his first appearance for his new team, the 27-year-old has already impressed his new teammates, having wowed the coaching staff.

    Marcus Rashford speaks during his Barcelona unveiling. Image: Getty

    Marcus Rashford speaks during his Barcelona unveiling. Image: Getty

    According to reporter Alex Pintanel, Rashford has been described as a ‘beast’ within the dressing room after taking part in his first training session at Barca.

    On X, Pintanel revealed: “In the locker room, they say he’s like a ‘beast’.”

    Rashford spent the second half of last season on loan at Aston Villa and showed glimpses of his ability, having starred against Paris Saint-Germain in the Champions League.

    He will be hoping to resurrect his career in Spain and he’s excited to get things started.

    “I’m very excited,” the England international told the club’s YouTube channel. “It’s a club where people’s dreams come true, they win big prizes.

    “What the club stands for means a lot for me. I feel like I’m at home and a big factor in my choice to come here is because it is a family place and a good place for good players to showcase their skills.”

    Marcus Rashford will wear the No.14 shirt at Barcelona following his move from Manchester United. Image: Getty

    Marcus Rashford will wear the No.14 shirt at Barcelona following his move from Manchester United. Image: Getty

    Rashford added: “Another factor is because the conversations I had with [Hansi Flick] were positive. What he did last season was terrific. To lead such a young team to a very successful season and come back to pre-season and still want to do more, it shows me everything I thought I knew about the club and it’s everything I wished.

    “I’m eager to learn the Barcelona way.”

    Continue Reading

  • NASA Sets Coverage for Agency’s SpaceX Crew-11 Launch, Docking

    NASA Sets Coverage for Agency’s SpaceX Crew-11 Launch, Docking

    NASA will provide coverage of the upcoming prelaunch and launch activities for the agency’s SpaceX Crew-11 mission to the International Space Station.

    Liftoff is targeted for 12:09 p.m. EDT, Thursday, July 31, from Launch Complex 39A at NASA’s Kennedy Space Center in Florida. The targeted docking time is approximately 3 a.m., Saturday, Aug. 2.

    Watch agency launch coverage on NASA+, Netflix, Amazon Prime and more. Learn how to watch NASA content through a variety of platforms, including social media.

    The SpaceX Dragon spacecraft will carry NASA astronauts Zena Cardman and Mike Fincke, JAXA (Japan Aerospace Exploration Agency) astronaut Kimiya Yui, and Roscosmos cosmonaut Oleg Platonov to the orbiting laboratory for a science mission. This is the 11th crew rotation mission and the 12th human spaceflight mission for NASA to the space station supported by the Dragon spacecraft since 2020 as part of the agency’s Commercial Crew Program.

    The deadline for media accreditation for in person coverage of this launch has passed. The agency’s media credentialing policy is available online. For questions about media accreditation, please email: ksc-media-accreditat@mail.nasa.gov.

    Media who need access to NASA live video feeds may subscribe to the agency’s media resources distribution list to receive daily updates and links.

    NASA’s mission coverage is as follows (all times Eastern and subject to change based on real-time operations):

    Saturday, July 26

    1 p.m. – Crew-11 arrival media event at NASA Kennedy with the following participants:

    • Zena Cardman, spacecraft commander, NASA
    • Mike Fincke, pilot, NASA
    • Kimiya Yui, mission specialist, JAXA
    • Oleg Platonov, mission specialist, Roscosmos

    Watch live coverage of the crew arrival media event on the NASA Kennedy’s social media accounts.

    This event is open to in person media only previously credentialed for this event. Follow @NASAKennedy on X for the latest arrival updates.

    Wednesday, July 30

    5:30 p.m. – Prelaunch news conference with the following participants:

    • Ken Bowersox, associate administrator, NASA’s Space Operations Mission Directorate
    • Steve Stich, manager, NASA’s Commercial Crew Program
    • Dana Weigel, manager, NASA’s International Space Station Program
    • William Gerstenmaier, vice president, Build and Flight Reliability, SpaceX
    • Sergei Krikalev, deputy director general, Manned and Automated Complexes, Roscosmos
    • Naoki Nagai, program manager, International Space Station, Human Spaceflight Technology Directorate, JAXA

    NASA will provide live coverage of the news conference on the agency’s YouTube channel.

    Media may ask questions in person and via phone. For the dial-in number and passcode, media should contact the Kennedy newsroom no later than one hour prior to the beginning of the news conference at: ksc-newsroom@mail.nasa.gov.

    Thursday, July 31

    8 a.m. – Launch coverage begins on NASA+, Netflix, and Amazon Prime.

    12:09 p.m. – Launch

    Following the conclusion of launch coverage, NASA will distribute audio-only discussions between Crew-11, the space station, and flight controllers during Dragon’s transit to the orbital complex. NASA+ coverage resumes at the start of rendezvous and docking and continues through hatch opening and the welcoming remarks. 

    1:30 p.m. – Postlaunch news conference with the following participants:

    • Ken Bowersox, associate administrator, NASA’s Space Operations Mission Directorate
    • Steve Stich, manager, NASA’s Commercial Crew Program
    • Dana Weigel, manager, NASA’s International Space Station Program
    • Sergei Krikalev, deputy director general, Manned and Automated Complexes, Roscosmos
    • Kazuyoshi Kawasaki, associate director general, Space Exploration Center/Space Exploration Innovation Hub Center, JAXA
    • Sarah Walker, director, Dragon Mission Management, SpaceX

    NASA will provide live coverage of the postlaunch news conference on the agency’s YouTube channel.

    Media may ask questions in person and via phone. Limited auditorium space will be available for in person participation. For the dial-in number and passcode, please contact the Kennedy newsroom no later than one hour prior to the beginning of the news conference at ksc-newsroom@mail.nasa.gov.

    Saturday, Aug. 2

    1 a.m. – Arrival coverage begins on NASA+.

    3 a.m. – Targeted docking to the space-facing port of the station’s Harmony module.

    4:45 a.m. – Hatch opening

    5:30 a.m. – Welcome ceremony

    All times are estimates and could be adjusted based on real-time operations after launch. Follow the space station blog for the most up-to-date operations information.

    Live Video Coverage Prior to Launch

    NASA will provide a live video feed of Launch Complex 39A approximately six hours prior to the planned liftoff of the Crew-11 mission. Pending unlikely technical issues, the feed will be uninterrupted until the prelaunch broadcast begins on NASA+, approximately four hours prior to launch. Once the feed is live, find it online at: http://youtube.com/kscnewsroom.

    NASA Website Launch Coverage

    Launch day coverage of the mission will be available on the NASA website. Coverage will include livestreaming and blog updates beginning no earlier than 8 a.m., July 31, as the countdown milestones occur. On-demand streaming video on NASA+ and photos of the launch will be available shortly after liftoff. For questions about countdown coverage, contact the NASA Kennedy newsroom at 321-867-2468. Follow countdown coverage on the commercial crew or Crew-11 blog.

    Attend Launch Virtually

    Members of the public may register to attend this launch virtually. NASA’s virtual guest program for this mission also includes curated launch resources, notifications about related opportunities or changes, and a stamp for the NASA virtual guest passport following launch.

    Audio Only Coverage

    Launch audio also will be available on Launch Information Service and Amateur Television System’s VHF radio frequency 146.940 MHz and KSC Amateur Radio Club’s UHF radio frequency 444.925 MHz, FM mode, heard within Brevard County on the Space Coast.

    Watch, Engage on Social Media

    Let people know you’re following the mission on X, Facebook, and Instagram by using the hashtags #Crew11 and #NASASocial. You may also stay connected by following and tagging these accounts:

    X: @NASA, @NASAKennedy, @Space_Station, @ISS National Lab, @SpaceX

    Facebook: NASA, NASAKennedy, ISS, ISS National Lab

    Instagram: @NASA, @NASAKennedy, @ISS, @ISSNationalLab, @SpaceX

    Coverage en Espanol

    Did you know NASA has a Spanish section called NASA en Espanol? Check out NASA en Espanol on X, Instagram, Facebook, and YouTube for additional mission coverage.

    Para obtener información sobre cobertura en español en el Centro Espacial Kennedy o si desea solicitar entrevistas en español, comuníquese con Antonia Jaramillo: 321-501-8425; antonia.jaramillobotero@nasa.gov; o Messod Bendayan: 256-930-1371; messod.c.bendayan@nasa.gov.

    NASA’s Commercial Crew Program has delivered on its goal of safe, reliable, and cost-effective transportation to and from the International Space Station from the United States through a partnership with American private industry. This partnership is opening access to low Earth orbit and the International Space Station to more people, more science, and more commercial opportunities. For almost 25 years, humans have continuously lived and worked aboard the International Space Station, advancing scientific knowledge and demonstrating new technologies that enable us to prepare for human exploration of the Moon as we prepare for Mars.

    For more information about the mission, visit:

    https://www.nasa.gov/commercialcrew

    -end-

    Joshua Finch / Claire O’Shea
    Headquarters, Washington
    202-358-1100
    joshua.a.finch@nasa.gov / claire.a.o’shea@nasa.gov

    Steven Siceloff / Stephanie Plucinsky
    Kennedy Space Center, Florida
    321-867-2468
    steven.p.siceloff@nasa.gov / stephanie.n.plucinsky@nasa.gov

    Joseph Zakrzewski
    Johnson Space Center, Houston
    281-483-5111
    joseph.a.zakrzewski@nasa.gov


    Continue Reading

  • Ongoing Research Aims to Alter Management of HR+ Breast Cancer After Frontline CDK4/6 Inhibition

    Ongoing Research Aims to Alter Management of HR+ Breast Cancer After Frontline CDK4/6 Inhibition

    Although data from the phase 3 SERENA-6 trial (NCT04964934) demonstrated progression-free survival (PFS) and quality-of-life (QOL) benefits with switching from first-line aromatase inhibitor (AI) plus CDK4/6 inhibitor therapy to camizestrant upon the detection of an ESR1 mutation in patients with hormone receptor–positive, HER2-negative advanced breast cancer, additional time to second progression (PFS2) and overall survival (OS) data are needed to support the adoption of molecularly-guided treatment switching in clinical practice, according to Laura Huppert, MD.

    Additionally, Huppert noted that dhese data, along with ongoing work with other novel endocrine therapies, could provide expanded and improved options for patients following progression on a CDK4/6 inhibitor–based regimen.

    Findings presented during the 2025 ASCO Annual Meeting showed that the median investigator-assessed PFS with camizestrant plus CDK4/6 inhibition (n = 157) was 16.0 months (95% CI, 12.7-18.2) vs 9.2 months (95% CI, 7.2-9.5) with continued AI plus CDK4/6 inhibition (n = 158; HR, 0.44; 95% CI, 0.31-0.60; P < .00001). The 12- and 24-month PFS rates with the camizestrant regimen were 60.7% and 29.7%, respectively. Respective rates with continued AI plus CDK4/6 inhibition were 33.4% and 5.4%.

    “If [the camizestrant combination] ends up being an approved regimen, it would definitely be a paradigm shift for how we’re treating breast cancer, because we would need to start monitoring circulating tumor DNA [ctDNA] and switching earlier,” Huppert, an assistant professor of medicine at the University of California, San Francisco School of Medicine, stated in an interview with OncLive®. “The PFS difference is very interesting and compelling; we just need a bit more data to know how we’ll ultimately utilize this in clinical practice.”

    In the interview, Huppert discussed the mechanistic differences between oral selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs); the current post–CDK4/6 inhibitor treatment landscape in hormone receptor–positive breast cancer; the clinical implications of the SERENA-6 trial for early intervention with camizestrant based on molecular progression; and how novel endocrine therapies could help improved outcomes for patients in later lines of therapy.

    OncLive: What is the distinction between oral SERDs and PROTACs in the hormone receptor–positive breast cancer space?

    Huppert: Both of these [drug classes represent] different ways to target estrogen receptor [ER] signaling. The idea is that if disrupting that signaling can prevent tumor cell growth. Oral SERDs work by binding to the ER and inducing its degradation, [thereby inhibiting] ER signaling. PROTACs are a novel class of molecules that work by using the cell’s own natural protein degradation system. They bring an enzyme in close proximity to the ER, which labels it for degradation, and then the cell’s own ubiquitination system and proteasome degrade it.

    At ASCO 2025, we saw the first [readout of] phase 3 data with a PROTAC [with vepdegestrant in the VERITAC-2 trial (NCT05654623)], which was interesting. It’s a first-in-class molecule and will potentially be a novel form of ER blocking that’s slightly different than oral SERDs and other agents we’ve had before.

    What are some of the available treatment options after a patient progresses on a frontline CDK4/6 inhibitor–based regimen?

    After progression on first-line AI plus CDK4/6 inhibitor therapy, we typically check next-generation sequencing [NGS] to see what mutations the tumor cells either have or have developed over time that might be targetable. For example, approximately 40% of patients develop an ESR1 mutation [during first-line therapy]. In these patients, we have a currently approved therapy, elacestrant [Orserdu], that can be utilized. If a patient has a PIK3CA, AKT, or PTEN mutation, capivasertib [Truqap] plus fulvestrant [Faslodex] is a currently approved option.

    If patients have none of these mutations, we have other options as well. We can use fulvestrant and a switch in CDK4/6 inhibitor, or everolimus [Afinitor] is still an option with fulvestrant or exemestane [Aromasin]. Of course, there are many novel therapies in this arena. Some are likely to be approved, and others are still in development. The second- and third-line endocrine therapy space is a rapidly evolving area at the moment.

    With SERENA-6 demonstrating a benefit in switching treatment following the emergence of an ESR1 mutation prior to radiographic progression, what could this mean for future treatment strategies in terms of earlier intervention?

    SERENA-6 was a phase 3 trial that evaluated whether it would be beneficial for patients on their first-line AI and CDK4/6 inhibitor [who develop an] ESR1 mutation but don’t have evidence of clinical progression by imaging to switch to [treatment with] an oral SERD, camizestrant, in that setting.

    It enrolled patients who were already receiving their AI and CDK4/6 inhibitor, and they were monitored every 3 months with ctDNA testing. Patients who developed an ESR1 mutation [without clinical progression were then] randomly assigned to either stay on their AI and CDK4/6 inhibitor with a placebo, or switch to camizestrant and CDK4/6 inhibitor with a placebo. They followed these patients over time, with the primary end point being PFS.

    What they saw was that patients who switched to camizestrant had improved PFS [by a] difference of [6.8] months between the 2 arms, which was definitely very interesting, compelling, and statistically significant data. [The results] also showed that there was improved time to deterioration of global health status and QOL [with this approach], which I thought was interesting as well.

    In this trial, PFS2 and OS [were also evaluated]. PFS2 [data] favored the switch to camizestrant, but these were not yet statistically significant. The data are not yet mature. OS data are also not mature.

    [SERENA-6] was an interesting and compelling study for multiple reasons. Historically, we wanted to keep patients on each treatment as long as possible until we see evidence of progression by scans or symptoms. However, this was looking at whether we should switch [treatment] at the time of molecular progression, rather than progression on scans.

    What still needs to be learned about the benefit of earlier treatment switching based on molecular progression in order to support adopting this approach in clinical practice?

    It will be important to look at PFS2 more as those data mature. Does this early switch help people do better on their next line of therapy? Ideally, we’re hoping for OS data to show whether switching early ultimately helps people live longer. We need more of follow-up data to know how to employ this [strategy] in the future.

    There are also ongoing trials looking at using oral SERDs from the start [of first-line treatment], rather than switching [from an AI to an] oral SERDs [with subsequent treatment]. We’ll have to see what those trials look like as well. All these moving pieces will help us figure out how to employ these data and what to do with them going forward.

    How could a potential approval of the SERENA-6 regimen affect clinical practice in terms of second-line treatment decision-making?

    If SERENA-6 is approved and a certain percentage of our patients develop the ESR1 mutation and switch to camizestrant, in the second-line setting, we would still want to check NGS and look for any new mutations that might be present, and then we can choose therapy accordingly.

    In patients who were on the SERENA-6 regimen and did switch to an oral SERD, it will be important to potentially think about other endocrine backbones or other combinations beyond just an oral SERD in the subsequent line. This is all the more reason we are excited to have novel endocrine therapy backbones, as well as novel targeted therapy partners, to offer more and more options in the second- and third-line settings.

    Despite the incorporation of novel endocrine therapies into the treatment paradigm, what unmet needs still exist for patients with hormone receptor–positive breast cancer after progression on a CDK4/6 inhibitor–based regimen?

    In general, patients experience the longest PFS on first-line therapy, which is typically an AI plus a CDK4/6 inhibitor. The duration of response generally shortens in the second- and third-line settings. There is hope that with the introduction of novel agents, it may be possible to achieve longer PFS in these later lines of therapy by utilizing new mechanisms of action with the endocrine therapy backbone, as well as novel targeted therapy combinations. Prolonging PFS in the second- and third-line settings remains an area of unmet need.

    Typically, patients receive 2 to 3 lines of endocrine therapy before becoming resistant and needing to transition to chemotherapy or antibody-drug conjugates. However, with emerging agents, it may be possible to extend the number of endocrine therapy lines. The goal is to prolong the endocrine-sensitive phase of disease by leveraging these novel agents, which are often oral and better tolerated than chemotherapy. Delaying the need for cytotoxic therapies may enhance both QOL and OS. Therefore, there is significant interest in optimizing treatment options in the second- and third-line settings.

    Reference

    Turner N, Mayer E, Park YH, et al. Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial. J Clin Oncol. 2025;43(suppl 17):LBA4. doi:10.1200/JCO.2025.43.17_suppl.LBA4

    Continue Reading